Latest News for: pi3k

Edit

Gedatolisib, a multitarget PI3K/AKT/mTOR inhibitor, plus fulvestrant with or without palbociclib for second-line treatment of patients with HR+/HER2-/ PIK3CA-WT advanced breast cancer: updated results from the randomized, phase 3 VIKTORIA-1 trial (Celcuity Inc)

Public Technologies 11 Dec 2025
... rapamycin complex; PAM, PI3K/AKT/mTOR; PI3K, phosphatidylinositol 3-kinase; PTEN, phosphatase and tensin entity; RTKs, receptor tyrosine kinases; TRAE, treatment-related adverse event; WT, wild-type.
Edit

PI3K Inhibitor Pipeline Drugs Insights Report 2025 Outlook: Latest Clinical Progress and Market Insights by DelveInsight

GetNews 28 Oct 2025
PI3K Inhibitor Overview ... PI3K Inhibitor Companies ... Company Name Inactive Products PI3K Inhibitor - Collaborations Assessment- Licensing / Partnering / Funding PI3K Inhibitor - Unmet Needs PI3K Inhibitor - Market Drivers and Barriers Appendix.
  • 1

Article Search

tools
×
×
×
×